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Introduction
Rituximab is a therapeutic anti-CD20 antibody used for
in vivo depletion of B cells.
However, the mechanisms of action are not fully under-
stood because clinical responses do not always correlate
with the extent and duration of B cell depletion.
Aim
This study was conducted to examine the effect of B cell
depletion on peripheral T cells from rheumatoid arthri-
tis patients.
Methods
RA patients received rituximab (1000 mg). Peripheral
blood samples were collected at baseline and at 30, 90
and 180 days postinfusion. The phenotype of T cell sub-
sets of peripheral blood from RA patients were examined
by cytometry and cytokine production was determined
by ELISA.
Results
According to our previous results, peripheral B cell deple-
tion was fully effective by 30 days. No changes in the per-
centage of CD3+, CD4+, CD8+ and NK cells were found.
There was a comparative progressive diminution of CD8
+CD45RO+ cells with recovery starting at 180 days.
DAS28 significantly correlated with CD8+CD45RO+ cells.
Since CD8+CD45RO+ diminution was coincident with
the clinical response measured as DAS28, we investigated
whether IL-15 could be responsible for this population
changes in rheumatoid arthritis patients. As expected
there was significant levels of IL-15 in the serum RA
patients (110 ± 31 pg/ml) compared to healthy donors
(< 10 pg/ml). Rituximab treatment decreased IL-15 levels
in serum from rheumatoid arthritis patients. Although, no
significant correlation was observed between IL-15 in the
serum and CD8+CD45RO+ cells, levels of IL-15 trans-
presented on the surface of neutrophils from RA patients
significantly correlated with CD8+CD45RO+ (p<0.01)
cells and CD8+CD45RO+/RA+ ratio (p<0.001).
Conclusion
This study demonstrates that rituximab treatment is able
to reduce IL-15 levels. This reduction could be responsi-
ble for tthe CD45RO+ changes during the follow-up.
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